JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1995; 26:826-835
© 1995 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feldman, L.
Right arrow Articles by Isner, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feldman, L.
Right arrow Articles by Isner, J.

Gene therapy for the vulnerable plaque

LJ Feldman and JM Isner

Department of Medicine (Cardiology), St. Elizabeth's Medical Center, Boston, Massachusetts 02135, USA.

Acute coronary events result from the rupture of an atherosclerotic plaque, leading to formation of an occlusive coronary thrombus. Recent developments in the field of gene transfer provide the opportunity to genetically modify cells involved in plaque rupture as well as thrombus formation and thus prevent acute coronary syndromes. A first approach consists of transferring genes, the product of which may stabilize the vulnerable plaque by reducing the plaque content in lipids and macrophages. Alternatively, the introduction into the atherosclerotic plaque of genes encoding for thrombolytic proteins or growth factors able to restore physiologic antithrombotic functions of endothelial cells may inhibit thrombus formation should the plaque rupture. The success of such strategies depends on the efficiency with which the transgene is introduced and expressed into the target cell, the duration of transgene expression and the ability of the transgene product to ultimately prevent plaque rupture or thrombus formation, or both.


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
L.G Melo, M Gnecchi, A.S Pachori, K Wang, and V.J Dzau
Gene- and cell-based therapies for cardiovascular diseases: current status and future directions
Eur. Heart J. Suppl., September 1, 2004; 6(suppl_E): E24 - E35.
[Abstract] [Full Text]

Home page
 J Am Coll CardiolHome page
I.-K. Jang, B. E. Bouma, D.-H. Kang, S.-J. Park, S.-W. Park, K.-B. Seung, K.-B. Choi, M. Shishkov, K. Schlendorf, E. Pomerantsev, et al.
Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound
J. Am. Coll. Cardiol., February 20, 2002; 39(4): 604 - 609.
[Abstract] [Full Text] [PDF]

Home page
 Vasc MedHome page
J. Dulak, A. Jozkowicz, A. Ratajska, A. Szuba, J. P Cooke, and A. Dembinska-Kiec
Vascular endothelial growth factor is efficiently synthesized in spite of low transfection efficiency of pSG5VEGF plasmids in vascular smooth muscle cells
Vascular Medicine, February 1, 2000; 5(1): 33 - 40.
[Abstract] [PDF]

Home page
 Cardiovasc ResHome page
R. Rabbani and E. J. Topol
Strategies to achieve coronary arterial plaque stabilization
Cardiovasc Res, February 1, 1999; 41(2): 402 - 417.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
L. J Feldman and G. Steg
Optimal techniques for arterial gene transfer
Cardiovasc Res, September 1, 1997; 35(3): 391 - 404.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
D. D. Heistad and F. M. Faraci
Gene Therapy for Cerebral Vascular Disease
Stroke, September 1, 1996; 27(9): 1688 - 1693.
[Abstract] [Full Text]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1995 by the American College of Cardiology Foundation.